{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:11:21Z","timestamp":1788610281798,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nano.2026.103015","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:28:49Z","timestamp":1787927329000},"page":"103015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Co-evolution of science and ethics in the clinical translation of nanocarriers for oncology: A perspective"],"prefix":"10.1016","volume":"76","author":[{"given":"Sobia","family":"Noreen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2026.103015_bb0005","first-page":"1","article-title":"Impact of nanocarrier mediated drug delivery systems: a deep dive into therapeutics and clinical management of breast cancer","author":"Hanif","year":"2026","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.nano.2026.103015_bb0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.medj.2022.12.001","article-title":"Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects","volume":"4","author":"Zhang","year":"2023","journal-title":"Med"},{"issue":"29","key":"10.1016\/j.nano.2026.103015_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"issue":"3","key":"10.1016\/j.nano.2026.103015_bb0020","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.103015_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114805","article-title":"Novel thiol-functionalized hyaluronic acid-based pH-responsive hydrogel: a promising mucoadhesive drug delivery approach toward the treatment of colorectal cancer","author":"Noreen","year":"2025","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.nano.2026.103015_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2025.1765965","article-title":"Nano-preparations in the design of drug delivery systems","volume":"7","author":"Noreen","year":"2026","journal-title":"Front Nanotechnol"},{"key":"10.1016\/j.nano.2026.103015_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104646","article-title":"Recent insights and applications of nanocarriers-based drug delivery systems for colonic drug delivery and cancer therapy: an updated review","author":"Noreen","year":"2025","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.nano.2026.103015_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2025.1548593","article-title":"Advancement in nanobubble technology: enhancing drug and nutraceutical delivery with focus on bioavailability, targeted therapy, safety, and sustainability","volume":"7","author":"Awlqadr","year":"2025","journal-title":"Front Nanotechnol"},{"key":"10.1016\/j.nano.2026.103015_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nyas.12403","article-title":"Nanomedicines: addressing the scientific and regulatory gap","volume":"1313","author":"Tinkle","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"02","key":"10.1016\/j.nano.2026.103015_bb0050","doi-asserted-by":"crossref","DOI":"10.22377\/ajp.v18i02.5444","article-title":"Nanocarrier-based formulations: regulatory challenges, ethical and safety considerations in pharmaceuticals","volume":"18","author":"Kardani","year":"2024","journal-title":"Asian J Pharm"},{"key":"10.1016\/j.nano.2026.103015_bb0055","series-title":"The Belmont report: ethical principles and guidelines for the protection of human subjects of research","volume":"Vol. 2","author":"US-NCPHSBBR","year":"1978"},{"key":"10.1016\/j.nano.2026.103015_bb0060","article-title":"Recent advances in cancer nanomedicine: from smart targeting to personalized therapeutics \u2014 pioneering a new era in precision oncology","volume":"36","author":"Younas","year":"2026","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.nano.2026.103015_bb0065","article-title":"From bench to bedside: advancing liposomal doxorubicin for targeted cancer therapy","volume":"19","author":"Ahmad","year":"2025","journal-title":"Results Surf Interfaces"},{"issue":"14","key":"10.1016\/j.nano.2026.103015_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142303","article-title":"Advances in doxorubicin chemotherapy: emerging polymeric nanocarriers for drug loading and delivery","volume":"17","author":"Bhadran","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.nano.2026.103015_bb0075","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/1061186X.2018.1437920","article-title":"Graphene-based nanocomposites: synthesis and their theranostic applications","volume":"26","author":"Madni","year":"2018","journal-title":"J Drug Target"},{"issue":"9","key":"10.1016\/j.nano.2026.103015_bb0080","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/nnm-2023-0318","article-title":"pH-sensitive docetaxel-loaded chitosan\/thiolated hyaluronic acid polymeric nanoparticles for colorectal cancer","volume":"19","author":"Noreen","year":"2024","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0085","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.103015_bb0090","series-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"1994"},{"issue":"11","key":"10.1016\/j.nano.2026.103015_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-082096","article-title":"Informed consent and risk communication challenges in antimicrobial clinical trials: a scoping review","volume":"14","author":"Shou","year":"2024","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.nano.2026.103015_bb0100","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/journalofethics.2016.18.9.peer2-1609","article-title":"The limits of informed consent for an overwhelmed patient: clinicians\u2019 role in protecting patients and preventing overwhelm","volume":"18","author":"Bester","year":"2016","journal-title":"AMA J Ethics"},{"issue":"9","key":"10.1016\/j.nano.2026.103015_bb0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMra1411250","article-title":"Enduring and emerging challenges of informed consent","volume":"372","author":"Grady","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2026.103015_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126488","article-title":"Long circulating nanocarriers: achievements and shortcomings of biomimetic approaches","volume":"689","author":"Shetab Boushehri","year":"2026","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.nano.2026.103015_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030379","article-title":"Clinical applications of targeted nanomaterials","volume":"17","author":"Kumar","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.nano.2026.103015_bb0120","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41416-022-02038-4","article-title":"The importance of long-term follow up of participants in clinical trials","volume":"128","author":"Cuzick","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2026.103015_bb0125","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.2147\/IJN.S333657","article-title":"Potential of nanocarrier-based drug delivery systems for brain targeting: a current review of literature","author":"Alotaibi","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.103015_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.103015_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102838","article-title":"Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials \u2014 insights from an expert virtual roundtable","volume":"76","author":"Yap","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.nano.2026.103015_bb0140","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","volume":"20","author":"Herdiana","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.103015_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106740","article-title":"Inclusion and diversity in clinical trials: actionable steps to drive lasting change","volume":"116","author":"Kelsey","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.nano.2026.103015_bb0150","series-title":"Nanotheranostics and Precision Oncology","first-page":"577","article-title":"Ethical and legal considerations in the use of nanotheranostics and precision medicine","author":"Khan","year":"2026"},{"key":"10.1016\/j.nano.2026.103015_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104885","article-title":"Regulatory landscape of nanotechnology and nanoplastics from a global perspective","volume":"122","author":"Allan","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"issue":"10","key":"10.1016\/j.nano.2026.103015_bb0160","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2026.103015_bb0165","article-title":"Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks","volume":"12","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nano.2026.103015_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2025.100127","article-title":"Nanomaterials for biomedical applications: addressing regulatory hurdles and strategic solutions","volume":"11","author":"Gujjar","year":"2025","journal-title":"Nano Trends"},{"issue":"3","key":"10.1016\/j.nano.2026.103015_bb0175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0180","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12951-024-02901-x","article-title":"Nanotechnology in healthcare, and its safety and environmental risks","volume":"22","author":"Ma","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"36","key":"10.1016\/j.nano.2026.103015_bb0185","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.2174\/0929867328666210406115529","article-title":"Regulatory considerations, challenges and risk-based approach in nanomedicine development","volume":"28","author":"Cs\u00f3ka","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.nano.2026.103015_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114083","article-title":"Clinical translation of nanomedicines: challenges, opportunities, and keys","volume":"181","author":"Younis","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.nano.2026.103015_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202310129","article-title":"Thiolated poly-and oligosaccharide-based hydrogels for tissue engineering and wound healing","volume":"34","author":"Noreen","year":"2024","journal-title":"Adv Funct Mater"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s11671-024-04118-1","article-title":"Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines","volume":"19","author":"Havelikar","year":"2024","journal-title":"Discov Nano"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s44301-025-00008-2","article-title":"Nanotechnology in medicine: a double-edged sword for health outcomes","volume":"1","author":"Fortune","year":"2025","journal-title":"Health Nanotechnol"},{"key":"10.1016\/j.nano.2026.103015_bb0210","series-title":"Language Barriers in Clinical Trials: Exploring Impacts on Continuity and Participants\u2019 Engagement and Effective Mitigation Strategies","author":"Das","year":"2025"},{"issue":"5","key":"10.1016\/j.nano.2026.103015_bb0215","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.drudis.2018.01.047","article-title":"Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities","volume":"23","author":"Agrahari","year":"2018","journal-title":"Drug Discov Today"},{"issue":"8","key":"10.1016\/j.nano.2026.103015_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/jep.70323","article-title":"Bearing the burdens of medical uncertainty","volume":"31","author":"Hofmann","year":"2025","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.nano.2026.103015_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1163392","article-title":"Ethical and legal challenges in nanomedical innovations: a scoping review","volume":"14","author":"Wasti","year":"2023","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.nano.2026.103015_bb0230","doi-asserted-by":"crossref","DOI":"10.1093\/ptj\/pzae059","article-title":"On \u201cIs clinical research as helpful to clinicians as it could be?\u201d Turolla A, Guccione AA, Tedeschi R, Pillastrini P. Phys Ther 2023;103:pzad060. doi:10.1093\/ptj\/pzad060","volume":"104","author":"Hinrichs-Kinney","year":"2024","journal-title":"Phys Ther"},{"key":"10.1016\/j.nano.2026.103015_bb0235","first-page":"106","article-title":"Consumer trust in digital brands: the role of transparency and ethical marketing","volume":"2","author":"Ali","year":"2025","journal-title":"Adv Consum Res"},{"key":"10.1016\/j.nano.2026.103015_bb0240","article-title":"Editorial: the changing focus of regulatory frameworks around the globe and the opportunities for harmonization","volume":"12","author":"Magrelli","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12913-026-14030-2","article-title":"Nanomedicine as an opportunity for equity achievements through cost-reduction in public healthcare for head and neck cancer treatment in Brazil","volume":"26","author":"de Andrade","year":"2026","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.nano.2026.103015_bb0250","series-title":"Advanced Bionanocomposite Materials: Innovations for Sustainable Development","first-page":"625","article-title":"Regulatory framework and standards on bionanocomposites manufacturing and applications: social impact and ethical considerations","author":"Chand","year":"2025"},{"key":"10.1016\/j.nano.2026.103015_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125202","article-title":"Navigating translational research in nanomedicine: a strategic guide to formulation and manufacturing","volume":"671","author":"Zhang","year":"2025","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.103015_bb0260","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s12672-025-02664-3","article-title":"Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics","volume":"16","author":"Ammar","year":"2025","journal-title":"Discov Oncol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:11:56Z","timestamp":1788606716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S1549963426001164"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.103015","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-evolution of science and ethics in the clinical translation of nanocarriers for oncology: A perspective","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.103015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103015"}}